GCATx focuses on developing small molecule drugs against genetically-defined high-value targets critical to disease mechanisms. A number of indications especially within oncology are driven by activating somatic mutations, providing highly validated targets for therapeutic intervention.
Our business model seeks to execute a scalable R&D and out-licensing strategy that minimizes scientific risk (rigorous target selection process) and development expense (working with reputable CROs).
The company has a proactive business development approach through seeking buy-in from potential industry partners in advance.
GCATx management team has extensive scientific, financial, business development, and strategic transaction experience within the Biopharma industry.
Our capital-efficient structure for drug discovery and development uniquely positions the company to create potential value for all stakeholders.